MedPath

Cytarabine

Generic Name
Cytarabine
Brand Names
Cytosar, Vyxeos
Drug Type
Small Molecule
Chemical Formula
C9H13N3O5
CAS Number
147-94-4
Unique Ingredient Identifier
04079A1RDZ
Background

A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p472)

Indication

For the treatment of acute non-lymphocytic leukemia, acute lymphocytic leukemia and blast phase of chronic myelocytic leukemia.

Cytarabine is indicated in combination with daunorubicin for the treatment of newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC) in adults and pediatric patients 1 year and older.

Associated Conditions
Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia, Acute Myeloid Leukemia With Myelodysplasia-Related Changes, Acute Promyelocytic Leukemia, Meningeal leukemia, Metastatic Malignant Neoplasm to the Leptomeninges, Non-Hodgkin's Lymphoma (NHL), Treatment-Related Acute Myeloid Leukemia, Blast phase Chronic myeloid leukemia
Clinical Trials
Related News

Jazz Pharmaceuticals Reports Strong Q1 2025 Performance with $898 Million in Revenue, Advances Pipeline with Zepzelca sNDA Submission

• Jazz Pharmaceuticals reported total revenues of $898 million in Q1 2025, with Xywav and Epidiolex showing strong year-over-year growth of 9% and 10% respectively. • The company submitted a supplemental New Drug Application for Zepzelca in combination with atezolizumab as maintenance therapy for first-line extensive-stage small cell lung cancer, based on promising Phase 3 trial results. • Jazz completed the acquisition of Chimerix, adding dordaviprone to its late-stage pipeline for H3 K27M-mutant diffuse glioma, with an FDA PDUFA target date of August 18, 2025.

Ivosidenib Plus CPX-351 Shows Promise in IDH1-Mutated AML and High-Risk MDS Trial

• Phase 2 trial demonstrates 100% overall response rate for newly diagnosed patients and 43% for relapsed/refractory patients with IDH1-mutated AML or high-risk MDS receiving ivosidenib/CPX-351 combination. • All responders achieved undetectable measurable residual disease levels, with newly diagnosed patients showing median overall survival of 29.3 months and relapsed/refractory patients reaching 12.0 months. • The combination therapy demonstrated an acceptable safety profile with manageable adverse effects, primarily including rash and ECG changes, with no reported differentiation syndrome or treatment-related deaths.

FDA Guidance Enables Moleculin to Streamline Phase 3 Trial for Novel AML Treatment AnnAraC

• Moleculin Biotech receives FDA feedback allowing a 10% reduction in Phase 3 trial size for AnnAraC, their combination therapy targeting refractory/relapsed Acute Myeloid Leukemia. • The MIRACLE Phase 3 study will evaluate high-dose cytarabine combined with two different doses of Annamycin (190 mg/m2 and 230 mg/m2) against placebo in 75-90 initial subjects. • Annamycin holds Fast Track Status and Orphan Drug Designations from both FDA and EMA, with preliminary efficacy data expected in second half of 2025.

Moleculin Biotech's Annamycin Shows Promise in Overcoming Treatment Resistance in AML

• Moleculin Biotech's Annamycin demonstrates the ability to overcome resistance to Venetoclax in acute myeloid leukemia (AML) based on preclinical and clinical data. • Preliminary clinical data from the MB-106 trial indicates a 60% complete remission rate in relapsed or refractory AML patients treated with Annamycin plus Ara-C. • Moleculin has received regulatory approval in Europe to begin recruiting for its Phase 3 MIRACLE trial, evaluating Annamycin in combination with Cytarabine for R/R AML. • The FDA has provided positive guidance on Moleculin's IND amendment, potentially accelerating the approval timeline for Annamycin in AML treatment.

SELLAS Life Sciences' GPS Shows Promise in Phase 3 AML Trial, IDMC Recommends Continuation

• The Independent Data Monitoring Committee (IDMC) recommended continuing SELLAS Life Sciences' Phase 3 REGAL trial of galinpepimut-S (GPS) in acute myeloid leukemia (AML). • Interim analysis showed GPS exceeded futility criteria with no safety concerns, indicating potential efficacy in AML patients achieving second complete remission. • Patients in the REGAL trial exhibited a median survival exceeding 13.5 months, compared to 6 months with conventional therapy in a similar Phase 2 study. • 80% of GPS-treated patients showed a specific T-cell immune response, surpassing previous Phase 2 study results, with final analysis planned upon reaching 80 events.

Triplet Therapies Show Promise in Treating Leukemias: ASH 2024 Highlights

• Novel triplet therapies are demonstrating significant positive results in treating relapsed/refractory and newly diagnosed leukemias, according to multiple clinical trials. • A revumenib-based triplet achieved an 82% overall response rate in relapsed/refractory AML patients with KMT2A or NUP98 rearrangements, offering an improved treatment option. • Ivosidenib, venetoclax, and azacitidine triplet showed a 94% overall response rate in IDH1-mutant hematologic malignancies, positioning it as a potential standard-of-care. • Pirtobrutinib, obinutuzumab, and venetoclax triplet yielded high rates of undetectable measurable residual disease in previously untreated CLL patients.

Senti Bio's SENTI-202 Shows Promise in Early AML Trial

• Senti Bio's SENTI-202 demonstrated encouraging initial results in a Phase 1 trial for relapsed/refractory acute myeloid leukemia (AML). • Two of three patients achieved complete remission with no detectable cancer cells after treatment with the lowest dose of SENTI-202. • The CAR-NK cell therapy was generally well-tolerated, with an adverse event profile consistent with lymphodepleting chemotherapy in AML patients. • Senti Bio plans to continue dose escalation and expects to report additional response and durability data in 2025.

CPX-351 Shows Promise but Highlights Treatment Challenges in Older AML Patients

• Phase 2 data suggests CPX-351 benefits older patients with secondary or high-risk AML, but optimal use requires further clarification. • The study achieved a complete remission (CR) or CR with incomplete hematologic recovery (CRi) rate of 49% after induction therapy. • Event-free survival (EFS) was 3.0 months, and overall survival (OS) was 7.4 months, with improved outcomes in patients undergoing stem cell transplantation. • Researchers emphasize the need for more effective therapies for specific AML patient subgroups, despite CPX-351's potential.

Decitabine Plus CHAG Regimen Shows Promise in Relapsed/Refractory AML

• A study shows that combining decitabine with the CHAG priming regimen yields a high complete remission rate (74.2%) in relapsed/refractory AML patients. • The overall response rate was 82.2%, with manageable side effects and no treatment-related deaths, suggesting a potential new treatment strategy. • The median relapse-free survival was 4.3 months, and the median overall survival was 7.75 months, warranting further investigation with larger studies. • Decitabine combined with CHAG may offer deeper remissions, with a significant number of patients achieving MRD-negative status after treatment.

Moleculin Biotech Accelerates Data Readout for Annamycin AML Trial

• Moleculin Biotech amended its Phase 3 MIRACLE trial protocol for Annamycin, aiming for accelerated approval in relapsed/refractory AML. • The amended protocol allows unblinding of preliminary efficacy and safety data after the first 45 subjects, speeding up data availability. • The company anticipates reaching the 45-subject milestone in H2 2025, potentially leading to earlier strategic partnerships. • The MIRACLE trial evaluates Annamycin combined with cytarabine (AnnAraC) against high-dose cytarabine in R/R AML patients.

Moleculin Biotech Accelerates Data Readout for Phase 3 AML Trial of Annamycin

• Moleculin Biotech has amended its Phase 3 MIRACLE trial protocol for Annamycin in relapsed/refractory AML, potentially accelerating its approval timeline. • The amended protocol allows for unblinding of preliminary efficacy and safety data after the first 45 subjects, expected in H2 2025. • The MIRACLE trial is evaluating Annamycin in combination with cytarabine (AnnAraC) versus high-dose cytarabine alone in R/R AML patients. • Moleculin anticipates that early data readout will facilitate strategic partnerships and de-risk financing for the ongoing pivotal trial.

Moleculin Accelerates Data Readout for Annamycin AML Trial

• Moleculin Biotech amended its Phase 3 MIRACLE trial protocol for Annamycin in relapsed/refractory AML, aiming for earlier data unblinding. • The amended protocol allows for unblinding of preliminary efficacy and safety data after the first 45 subjects are treated. • Moleculin anticipates reaching 45 subjects in the second half of 2025, potentially accelerating strategic partnerships. • The MIRACLE trial is evaluating Annamycin in combination with cytarabine (AnnAraC) and remains on track for the first subject treated in Q1 2025.

Moleculin Biotech Accelerates Annamycin Phase 3 AML Trial Data Readout to H2 2025

• Moleculin Biotech accelerates the unblinding of preliminary data for its Phase 3 MIRACLE trial of Annamycin plus cytarabine in relapsed/refractory AML patients. • The amended protocol allows for earlier assessment of efficacy and safety across three arms after the first 45 subjects, potentially speeding up partnering discussions. • The company anticipates reaching 45 subjects in H2 2025, with additional unblinding planned for 2026, informing the optimal dose for Part B of the trial. • Annamycin holds Fast Track Status and Orphan Drug Designation from the FDA and EMA for relapsed or refractory AML, potentially expediting its approval process.

Moleculin Biotech's Annamycin Phase 3 Trial for Relapsed/Refractory AML Receives IRB Approval

• Moleculin Biotech has secured IRB approval for its Phase 3 MIRACLE trial, evaluating Annamycin with cytarabine for relapsed/refractory AML. • The MIRACLE trial employs an adaptive design, initially randomizing patients to different Annamycin doses to optimize safety and efficacy. • Annamycin holds Fast Track Status and Orphan Drug Designation from the FDA and EMA for relapsed/refractory AML treatment. • Enrollment for the MIRACLE trial is anticipated to begin in the first quarter of 2025, marking a significant step toward a potential new AML therapy.

Moleculin Biotech's Annamycin Advances to Phase 3 Trial for Relapsed/Refractory AML

• Moleculin Biotech's Annamycin receives IRB approval to begin a Phase 3 clinical trial (MIRACLE) for relapsed or refractory AML. • The MIRACLE trial will evaluate Annamycin in combination with cytarabine, with potential for accelerated FDA approval. • The adaptive trial design will optimize Annamycin dosage based on safety, pharmacokinetics, and efficacy data from initial subjects. • Annamycin holds FDA Fast Track Status and Orphan Drug Designation for R/R AML, and Orphan Drug Designation from the EMA.

Moleculin Biotech's Annamycin Phase 3 Trial for Relapsed/Refractory AML Receives IRB Approval

• Moleculin Biotech has secured IRB approval for its Phase 3 MIRACLE trial, evaluating Annamycin with cytarabine for relapsed/refractory AML. • The MIRACLE trial employs an adaptive design, initially randomizing subjects to different Annamycin doses to optimize safety and efficacy. • The company anticipates commencing enrollment in the first quarter of 2025, aiming for potential accelerated approval of Annamycin. • Annamycin holds Fast Track Status and Orphan Drug Designation from the FDA and EMA for relapsed/refractory AML.

Moleculin Biotech's Annamycin Shows Promise in R/R AML, Phase 3 Trial Launching in Q1 2025

• Moleculin Biotech is set to begin dosing in its Phase 3 MIRACLE trial of Annamycin plus cytarabine for relapsed/refractory AML in Q1 2025, designed for potential accelerated approval. • Preliminary data from the MB-106 Phase 1B/2 AML trial shows the median durability of complete response composite (CRc) continues to increase, now exceeding eight months. • Annamycin's potential to significantly alter the AML treatment landscape was highlighted at a recent KOL event, underscoring its clinical importance. • The company is advancing Annamycin for soft tissue sarcoma lung metastases, with final data readout from the MB-107 trial expected in 2025.

GlycoMimetics' Uproleselan Shows Promise in Acute Myeloid Leukemia Trials

• GlycoMimetics will present Phase 3 trial data on uproleselan plus chemotherapy in relapsed/refractory AML at the ASH Annual Meeting. • Updated Phase 1 results of uproleselan with azacitidine and venetoclax in treatment-naive AML will also be presented. • Final Phase 2 data of uproleselan combined with cladribine and low-dose cytarabine for treated secondary AML will be shared.

Fosun Pharma's Innovative Drug Receives Registration Acceptance in China

• Shanghai Fosun Pharmaceutical Group announced that its innovative drug has been accepted for registration in China, marking a significant regulatory milestone. • The acceptance indicates progress toward potential market approval, which could provide a new treatment option for patients in China. • This development underscores Fosun Pharma's commitment to bringing innovative pharmaceutical products to address unmet medical needs in the region.

Jazz Pharmaceuticals Advances Pipeline with Zanidatamab BLA Acceptance and Strong Financial Performance

• Jazz Pharmaceuticals' Biologics License Application (BLA) for zanidatamab, a HER2-targeted bispecific antibody, has been accepted by the FDA with Priority Review for biliary tract cancer. • The company reported strong financial results in 2023, with over $3.8 billion in total revenue and $1.6 billion in cash reserves, supporting continued investment in R&D. • Jazz Pharmaceuticals is actively expanding its oncology and neuroscience portfolio through strategic collaborations and internal development, focusing on unmet medical needs. • Key products like Xyrem, Xywav, Zepzelca, Rylaze, and Epidiolex continue to drive revenue, while ongoing trials aim to broaden indications and improve patient outcomes.
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy